氧化芍药苷
| 中文名称 | 氧化芍药苷 |
|---|---|
| 中文同义词 | 羟基芍药苷;氧化芍药苷(标准品);氧化芍药苷;羟基芍药苷(氧化芍药苷);氧化芍药苷,羟基芍药苷(标准品);OXYPAEONIFLORIN 氧化芍药苷;氧化芍药苷?, >98%;氧化芍药苷(羟基芍药苷)对照品, |
| 英文名称 | oxypaeoniflora |
| 英文同义词 | oxypaeoniflora;Nsc258310;Oxypeoniflorin;Oxypaeoniflorin, >98%;β-D-Glucopyranoside, (1aR,2S,3aR,5R,5aR,5bS)-tetrahydro-5-hydroxy-5b-[[(4-hydroxybenzoyl)oxy]methyl]-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl;((2S,2aR,2a1S,3aR,4R,5aR)-4-hydroxy-2-methyl-2a-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-1,5-dioxa-2,4-methanocyclobuta[cd]pentalen-2a1-yl)methyl 4-hydroxybenzoate;[[(1aR)-3aβ,5,5aβ,5b-Tetrahydro-5β-hydroxy-5bβ-[[(4-hydroxybenzoyl)oxy]methyl]-2-methyl-2α,5-methano-3,4-dioxa-1H-cyclobuta[cd]pentalen]-1aβ(2H)-yl]β-D-glucopyranoside;oxypaeoniflorin |
| CAS号 | 39011-91-1 |
| 分子式 | C23H28O12 |
| 分子量 | 496.46 |
| EINECS号 | |
| 相关类别 | 对照品;植提标准品;中药对照品;标准品;植物提取物;芍药苷系列;标准品-对照品;标准品-中药标准品;The group of Paeoniflorin;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;标准品 -中药标准品;其它萜类;标准品，对照品;皂苷 |
| Mol文件 | 39011-91-1.mol |
| 结构式 |  |
氧化芍药苷 性质
| 熔点 | >162°C (dec.) |
|---|---|
| 沸点 | 737.1±60.0 °C(Predicted) |
| 密度 | 1.71±0.1 g/cm3(Predicted) |
| 储存条件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 形态 | 固体 |
| 酸度系数(pKa) | 8.16±0.15(Predicted) |
| 颜色 | 白色至浅黄色 |
| 稳定性 | 吸湿性 |
Oxypaeoniflorin (OPA; 0.1-10 µM; 8 hours) obviously reversed the hypoxia/reoxygenation (H/R)-induced decrease in cell activity and increase in apoptosis of H9c2 cells. Oxypaeoniflorin inhibits apoptosis by activating the Sirt1 (silent information regulator factor 2 related enzyme 1)/Foxo1(forkhead transcription factor FKHR) signaling pathway in myocardial tissues and H9c2 cells.
Oxypaeoniflorin (0-30 μM) attenuates inflammatory effects via regulation of the toll-like receptor (TLR), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases signaling pathways in LPS-stimulated RAW264.7 cells.
Oxypaeoniflorin (OPA; 10-40 mg/kg; intragastrical administration; every day; for 30 days) treatment significantly reduces disruption of cardiac function and improves the indicators of ejection fraction (EF) and fractional shortening (FS). Oxypaeoniflorin significantly reduces the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT).
| Animal Model: | C57BL/6 male mice (6-8 weeks of age, 20-25 g) bearing myocardial ischemia/reperfusion (MI/R) injury |
| Dosage: | 10 mg/kg, 20 mg/kg, 40 mg/kg |
| Administration: | Intragastrical administration; every day; for 30 days |
| Result: | Significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS). |
药理药效:有抗炎镇痛、调节免疫、治疗风湿性关节炎等作用
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-N0748 | Oxypaeoniflorin | 1 mg | 660元 | |
| 2024/01/25 | HY-N0748 | 氧化芍药苷 Oxypaeoniflorin | 39011-91-1 | 5mg | 1650元 |